February 19, 2019

Is fortnightly FIX feasible?

Bioverativ’s B-LONG and B-YOND studies demonstrated the long-term safety and efficacy of its EHL FIX, rFIXFc, when administered every 7 days to >14 days. Now, a post hoc analysis of the small subgroup of patients who used a dose interval of 14 days or longer has shown that control of bleeding was similar to that of the study population overall (Res Pract Thromb Haemost 2018;3:109-113). Over a period of 3.4 years, the median overall annualised bleed rate in 18 patient was 1.6 (interquartile range 0.6-2.7) and the median spontaneous annualised bleed rate was 0.7 (0.3-1.1) .